Bio-Thera’s BAT4406F Gets NMPA Nod for MCD and FSGS Clinical Trials
Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced that its investigational drug, BAT4406F injection, has received approval...
Drug
Huadong Medicine Receives NMPA Approval for HDM2012 Clinical Trials in Advanced Solid Tumors
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clinical trial approval...
NMPA Approves World’s First Plant-Based Human Albumin for Liver Cirrhosis Treatment
China’s National Medical Products Administration (NMPA) has approved the world’s first plant-based human albumin, a...
Jumpcan Pharmaceutical’s Jike Shu Approved by NMPA for Influenza A and B Treatment
Shanghai-based Jumpcan Pharmaceutical (SHA: 600566) announced that its independently developed Class 1 innovative drug, Jike...
Novo Nordisk’s Ozempic Approved for Kidney Protection in China, Pioneering Glycemic and Renal Control
The National Medical Products Administration has granted approval to Novo Nordisk’s (NYSE: NVO) once-weekly semaglutide...
Sarepta Therapeutics Announces 500 Employee Layoffs After FDA Elevidys Trial Suspension
US-based Sarepta Therapeutics, a subsidiary of Sanofi (NASDAQ: SNY), announced the layoff of approximately 500...
Youcare Pharma Subsidiary Gains NMPA Clearance for Phase I Study of siRNA Hypertension Drug YKYY029
China-based Youcare Pharma (SHA: 688658) announced that its subsidiary Youcare InnoTech and partner Hangzhou Tianlong...
GSK’s Blenrep Fails to Win FDA Advisory Committee Support for Relapsed Multiple Myeloma
UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced that the US Food and Drug Administration (FDA) Oncologic...
CanSino Bio Receives NMPA Approval for Phase I/II Trial of Recombinant Polio Vaccine
China-based CanSino Biologics Inc., (HKG: 6185) announced that it and its subsidiary CanSino (Shanghai) Biotechnology...
Yifan Pharma’s Generic Glycerol Phenylbutyrate Accepted for NMPA Review
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced that the National Medical Products Administration (NMPA)...
Hengrui Pharmaceuticals’ SHR-8068 Gains NMPA Approval for NSCLC and Colorectal Cancer Trials
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the National Medical...
Fosun Pharma’s Zhejiang Xinghao Unit Initiates Phase Ib Study for COPD DPP-1 Inhibitor XH-S004
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its Zhejiang Xinghao...
Legend Biotech’s Carvykti Achieves USD 439 Million in Q2 2025 Sales
China-based Legend Biotech Corporation (NASDAQ: LEGN) reported that sales of Carvykti reached USD 439 million...
Takeda’s Oveporexton Meets All Endpoints in Phase 3 Narcolepsy Type 1 Trials
Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) announced that both Phase 3 randomized, double-blind, placebo-controlled...
Daiichi Sankyo and AstraZeneca Submit Enhertu Application for HER2-Positive Gastric Cancer in China
Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) have submitted a supplemental new-drug application...
Hainan Boao Research Hospital Secures Approval for China’s First Medical-Food Import for Rare Metabolic Disorders
Hainan Boao Research Hospital, operated by Shanghai’s Ruijin Hospital, has obtained provincial approval to import...
Sanofi’s Gene Therapy SAR446597 Secures FDA Fast Track for Geographic Atrophy
France-based Sanofi (NASDAQ: SNY) announced that its one-time intravitreal gene therapy SAR446597 has received FDA...
Hengrui Pharma and Kailera Announce Positive Phase III Results for HRS9531 in Obesity Treatment
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) and its US partner Kailera Therapeutics, Inc....
Haisco Pharma Receives FDA Approval for Clinical Trials of Autoimmune Drug HSK47388
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that it has received clinical trial...
AstraZeneca’s Baxdrostat Meets Primary and Secondary Endpoints in Phase III BaxHTN Trial
UK-based AstraZeneca (AZ, NASDAQ: AZN) announced that baxdrostat has achieved both primary and secondary endpoints in the...